Lava Therapeutics B.V. is a biotech company that develops proprietary Vγ9Vδ2 T-cell engagers based on the scientific advancements of the VU University Medical Center in Amsterdam.

The objective is to develop cost-effective next-generation immune oncology biopharmaceuticals delivering the primary targeted treatment in combination with immune recruiting and activating functionality.


Ton Adang

Ton Adang worked at several biotech companies and at Merck/MSD, Schering-Plough and Organon in research and development positions with increasing responsibilities.
Read more

Hans van der Vliet

Hans van der Vliet is a medical oncologist and associate professor at the department of medical oncology of the VU University medical center-Cancer Center Amsterdam.
Read more

Paul W.H.I. Parren

PhD, EVP Research & Development

Paul Parren is an expert in antibody research, translational science and drug development. He is a professor of molecular immunology at the Leiden University Medical Center.

Read more


A recent meta-analysis of expression signatures from ~18,000 human tumors with overall survival outcomes demonstrated that intra-tumoral γδ T-cell signatures constituted the most favorable cancer-wide prognostic cell population across 39 malignancies [1].

Moreover, activation of residing Vγ9Vδ2 T-cells or adoptive transfer of Vγ9Vδ2 T-cells can result in clinically significant tumor responses [2-5].

LAVA’s Vγ9Vδ2 T-cell engagers uniformly and specifically bind to the conserved (monomorphic) T-cell receptor of Vγ9Vδ2 T-cells that constitute a unique proinflammatory immune effector cell population, providing a consistent response and avoid generalized T cell activation known to induce side effects and to reduce anti-tumor effects. The cells exhibit potent cytotoxicity and interferon-γ secretion and HLA-unrestricted tumor cell killing and have antigen-presenting capabilities for αβ-T cells promoting the development of  adaptive immune responses.

Proof of principle has been established by in vitro and in vivo studies in which Vγ9Vδ2 T-cell engagers demonstrate potent tumor lysis independent of signaling escape mechanisms.

The company is working on several lead bispecific Vγ9Vδ2 T-cell engager candidates progressing towards the clinic.


Lava develops proprietary bispecific Vγ9Vδ2 T-cell engagers for selected tumor targets. Pharmaceutical companies with an interest to use Lava’s Vγ9Vδ2 T-cell engagers for own tumor targets or with an interest in Lava’s lead projects should contact Lava via info@lavatherapeutics.com.

Collaborations are a key part of our business strategy and we are actively seeking new partnerships with companies whom are interested in licensing our products and proprietary technologies.


Lava Therapeutics Raises EUR 16 Million to Advance Bispecific Gamma-Delta T Cell Engager Platform. Biologics Expert Paul Parren Joins as Head of R&D.

Lava Therapeutics licenses leading edge Vγ9Vδ2 T-cell immune oncology assets



Lava Therapeutics is expanding its team with talented people having an entrepreneurial mindset.

Senior Protein Scientist/Molecular Biologist

If you recognize yourself in one of our job descriptions and feel excited about contributing to the development of novel cancer treatments based on our first in class γδ T cell engaging bispecific antibodies, let us know.

Application letters can be sent to info@lavatherapeutics.com


+31 8 506 573 44

Onderwijsboulevard 225
5223 DE, ’s-Hertogenbosch